I am not privy to the discussions with BP so I’m not sure how...

I am not privy to the discussions with BP so I’m not sure how large the delta is between PR's expectations and what is being offered but one needs to consider the opportunity cost of delaying a deal.

By delaying a deal, PAR will potentially dilute shareholders, delay trials for other indications that could also be lucrative (just see Mozz's long list), keep focus away from the science as cash management/raising will be critical, limit the value extracted from a CR as the share price will most probably remain heavily discounted, inability to make decisions based on what’s best for the company due to financial considerations (i.e., to hire the right people (marketing, public relations, and slick US sales guys).

Need to consider the big picture here and i'm not sure if the current path taken is the prudent one.